The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus

Archives of Internal Medicine

Volumn 165, Issue 2, 2005, Pages 161-168

  Sowers, James R ^a,i   White, William B ^b   Pitt, Bertram ^c   Whelton, Andrew ^d   Simon, Lee S ^e   Winer, Nathaniel ^a   Kivitz, Alan ^f   Van Ingen, Hein ^g   Brabant, Thomas ^h   Fort, John G ^g  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f Altoona Center for Clinical Research   (United States)

^g PFIZER INC   (United States)

^h Krankenhaus St Joseph Stift Bremen   (Germany)

ⁱ University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CREATININE; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; OUTCOMES RESEARCH; PAIN ASSESSMENT; PATIENT MOBILITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGIDITY; SCORING SYSTEM; SYMPTOM; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD GLUCOSE; BLOOD PRESSURE DETERMINATION; CYCLOOXYGENASE INHIBITORS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LACTONES; MALE; MIDDLE AGED; NAPROXEN; OSTEOARTHRITIS; PROBABILITY; PYRAZOLES; RISK ASSESSMENT; SULFONAMIDES; SULFONES; TREATMENT OUTCOME;

EID: 19944432721     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.2.161     Document Type: Article

References (36)

1. Sowers JR, Haffner S, Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension. 2002;40:781-788.
2. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134-1146.
3. Gaede P, Vedel P, Larsen N, Jensen JVH, Parving HH, Pedersen O. Multifactional intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-392.
4. Singh G, Miller JD, Lee FH, Pettitt D, Russell MW. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. Am J Manag Care. 2002;8(15 suppl):S383-S391.
5. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153:477-484.
6. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure: a meta-analysis. Ann Intern Med. 1994;121:289-300.
7. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106:13S-24S.
8. Palmer R, Weiss R, Zusman RM, Haig A, Flaven S, MacDonald B. Effects of nabumetone, celecoxib and Ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. Am J Hypertens. 2003;16:135-139.
9. FDA Advisory Committee Background Information. Cardiovascular-Renal Safety Review (VIGOR). Merck Research Laboratories, Rofecoxib NDA 21-042:57-59. Available at: http://www.fda.gov/ohrms/dockets/ac/cder01.htm#Arthritis. Accessed February 8, 2001.
10. Whelton A, White WB, Bello AE, Puma JA, Fort JG; SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients 265 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959-963.
11. White WB, Kent J, Taylor A, Verburg KM, Lefkowitz JB, Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension. 2002;39:929-934.
12. American Diabetes Association. Position Statement: treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26(suppl 1):S80-S82.
13. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum. 1986;29:1039-1049.
14. Altman R, Alarcon G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the hip. Arthritis Rheum. 1991;34:505-514.
15. Bellamy N. Osteoarthritis clinical trials: candidate variables and clinimetric properties. J Rheumatol. 1997;24:768-778.
16. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833-1840.
17. Mansoor GA, McCabe EJ, White WB. Long-term reproducibility of ambulatory blood pressure. J Hypertens. 1994;12:703-708.
18. Physician Drug Diagnosis Audit (PDDA). Scott-Levin Inc; 2000. Available at: http: //www.quintiles.com/productsandservices/informatics/scottlevin /productsandservices/marketingaudits/pdda. Accessed August 28, 2004.
19. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM; for the SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001;8:85-95.
20. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003;107:405-409.
21. Widlansky ME, Price DT, Gokce N, et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension. 2003;42:310-315.
22. McKenna F, Weaver A, Fiechtner JJ, Bello AE, Fort JG. COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study. J Clin Rheumatol. 2001;7:151-159.
23. Gibofsky A, Williams GW, McKenna F, Fort JG, Comparing the efficacy of COX-2 specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum. 2003;48:3102-3111.
24. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA. 2002;287:64-71.
25. American College of Rheumatology Subcommittee on Osteoarthritis Guide-lines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum. 2000;43:1905-1915.
26. American Geriatric Society Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc. 2002;50 (suppl):S205-S224.
27. Simon LS, Lipman AG, Jacox AK, et al. Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis. 2nd ed. Glenview, III: American Pain Society; 2002:44.
28. Curb JD, Pressel SL, Cutler JA, et al; Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension [published correction appears in MMA. 1997;277:1356]. JAMA. 1996;276:1886-1892.
29. Curb JD, Pressel SL, Cutler JA, et al; Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension [published correction appears in MMA. 1997;277:1356]. JAMA. 1996;276:1886-1892.
30. Tuomilehto J, Rastenyte D, Birkenhager WH, et al; Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677-684.
31. Clement DL, DeBuyzere ML, DeBacquer DA, et al. Prognostic value of ambulatory blood pressure recordings in treated hypertension. N Engl J Med. 2003;348:2407-2415.
32. White WB. Ambulatory blood-pressure monitoring in clinical practice. N Engl J Med. 2003;348:2377-2378.
33. Staessen JA, Thijs L, Fagard R, et al; Systolic Hypertension in Europe Trial Investigators. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA. 1999;282:539-546.
34. Bjorklund K, Lind L, Zethelius B, et al. Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. Circulation. 2003;107:1297-1302.
35. Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004;44:140-145.
36. White WB. Hypertension associated with therapies to treat arthritis and pain. Hypertension. 2004;44:123-124.